SK looked me in the eye three years ago and said, "I believe Bavi works". And I believed him. That is, I believed he was sincere in his belief. I did not believe unarmed, "naked" immunogenic Bavi was going to make a significant difference in the fight against solid cancer. If you remember, Bavi was originally a double-armed MAB missile which could carry a payload of cytotoxins in one hand, and attach to the "flipped" membrane -PS antigen with the other. But then reality (scientific reality) intervened in that scheme just as it did with Bavi as a better Avastin. I believed SK was sincere, and as a Bavi pioneer and insider that he had more information that I. That too was an item of faith. But I am a pretty good judge of men, and I think he was, and probably still is, sincerely a believer in Bavi... and that the recent PIII results must have been a crushing surprise to him.
However, having been a pioneering investigator in one of the seminal "discoveries" and new treatments of the last century, I saw firsthand how much its inventor believed during that discovery's debut...and how utterly unrealistic his beliefs were. That is the bad news. The good news is that even if that invention and this one, Bavi, did not turn out to be all the inventors believed them to be at the time, this one, Bavi, will be good enough for several applications...none of which will be solid cancers. As stockholders we have footed the bill to determine that this monoclonal antibody is safe, and (in my opinion) it is a good bet that Bavi or other similar anti-phospholipid antibodies will be found to be clinically applicable. PPHM has the inside track in this seminal area of inquiry, and we must encourage continued preeminence in the field.
